
Darryl Kato, research scientist for Gilead Sciences Inc., works on the synthesis of a potential HCV drug candidate in the lab in Foster City, California, U.S., on Wednesday, Jan. 8, 2012. Photographer: David Paul Morris/Bloomberg *** Local Caption *** Darryl Kato
David Paul Morris/Bloomberg